Dental Caries in ChildrenNCT05645029
Evaluation of Glass Ionomer Cement Modified With Chlorhexidine and Titanium Dioxide in Primary Molars (RCT)
A study testing glass ionomer-chlorhexidine, glass ionomer-titanium dioxide powder and glass ionomer in people with Dental Caries in Children, run by Ain Shams University at 1 site in Egypt.
Trial summary
to investigate the effect of modifying GIC with different formulations on the antibacterial activity and clinical performance in reference to unmodified glass ionomer restorative materials. Read more about this study
- Who is it for?
- Ages 4 to 8 yearsHealthy volunteers can take part
- Conditions the study is for
- Dental Caries in Children
- What is being tested?
- glass ionomer-chlorhexidine, glass ionomer-titanium dioxide powder and glass ionomer
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 39 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Sep 2022to 15 Nov 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 4 to 8 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- The teeth will be primary molars selected from patients presented to the outpatient clinic that are
- Healthy patients.
- Children having at least one primary molar with only occlusal caries having dentine lesions (ADA caries classification system mostly 1 or 2 please check)
- Dentine caries must be apparent visually or radiographically
Who cannot join
- .Teeth with pulp involvement, those suffering from pain, irreversible pulpits or pulp necrosis.
- Patients with history of active para-functional oral habits, xerostomia.
- Patients who will have difficulties in cooperating
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Antimicrobial Activity and Clinical Performance of Glass Ionomer Cement Modified With Chlorhexidine and Titanium Dioxide in Primary Molars: A Randomized Clinical Trial
to investigate the effect of modifying GIC with different formulations on the antibacterial activity and clinical performance in reference to unmodified glass ionomer restorative materials.
Read the detailed description
The study will be a randomized clinical trial, with a 1:1:1 allocation ratio and parallel arms that will enroll children from the outpatient clinic of pediatric dentistry department, Ain shams University Blinding: Enrolled children, assessors and statistician will be blinded. Randomization: block randomization with blocks of 6. A maximum of 2 primary molars per patient will receive the same treatment.
Allocation concealment: Allocation will be done just before placement of a restoration to avoid performance bias during the cavity preparation. The envelope will be only checked after cavity preparation when the filling material will be chosen
Groups Teeth will be randomly allocated to 3 groups all groups will receive the same cavity preparation and then a different restoration.
- Group A: glass ionomer powder will be mixed with chlorhexidine
- Group B: glass ionomer will be mixed with titanium dioxide powder.
- Group C: will be the positive control, glass ionomer with no additives
Sample Size The sample size: A total number is 39 (13 in each group) is calculated using Epicalc program version 1.02 assuming a power of 80 % and alpha=0.05. The sample size is based on percentage of success of ART restorations at 9 months follow up (GIC with chlorhexidine and GIC with miswak) was 60% and 90%, respectively.13
Intervention:
Teeth will be randomly allocated to the three groups. Care givers and patients involved will be informed about the study procedures, an informed consent form and assent will be obtained. Group A: Conventional glass ionomer cement (Fuji IX, GC, Tokyo, Japan) will be used and modified by incorporating CHX diacetate (0.5% wt) into the powder of the glass ionomer (Fuji IX, GC, Tokyo, Japan) Group B: Conventional glass ionomer cement (Fuji IX, GC, Tokyo, Japan) will be used and modified by incorporating titanium dioxide (3% wt) in glass-based powder component of the GIC.
Group C: Conventional glass ionomer
Cavity preparation and baseline sampling Rubber dam will be placed for isolation of the designated teeth. A step wise caries removal technique will be employed28. Access to the cavity was created using a high-speed dental handpiece fitted with a Meisinger (Hager \& Meisinger - Germany) round diamond bur (801G-16) , and all the caries on the lateral walls, caries in the dentine-enamel junction and undermined enamel was removed.
Using a discoid Lascod (Lascod S.p.A Italy) excavator (#1) elective removal of superficial soft necrotic dentine was attempted, leaving behind demineralized wet, leathery dentine centrally on the pulpal wall (Leathery dentine is characterized by being removed in flakes by the excavator) 8,27 A different sterile excavator of the size will be used with very light pressure to take a sample of dentine from the center of the cavity floor center, the sample will be inserted in a brain heart infusion tube and sent to the microbiology lab within 1 hour then added to the culture to measure the bacterial load for the baseline sample by measuring the colony forming units (CFU) 29,30. Blood agar will be used to quantify the total bacterial count, while mitis-salivaris -bacitracin agar will be used to selectively quantify S.mutans.
After cavity preparation, an endodontic file will be used to record the depth of the cavity to aid with the re-entry, and then the operator will reveal the patient's group by opening an envelope. GC cavity conditioner" (GC Japan) will be applied to the cavity walls for 20 seconds leaving the floor unconditioned then the material will be packed into the cavity using a ball burnisher and pressed into it with a petroleum jelly covered gloves for 30 s (press finger technique). Then the excess material will be removed using a carver, and occlusion will be checked and adjusted, then Equia coat varnish (GC Japan) will be applied.
Follow-up The patients will be recalled at 6 and 9 months for clinical performance evaluation by the USPHS evaluation criteria (table 1). Visual and clinical inspection with 3.5x magnification will be done with the help of a sharp explorer by a blinded secondary investigator.
- Conditions
- Dental Caries in Children
- Being tested
- glass ionomer-chlorhexidine, glass ionomer-titanium dioxide powder, glass ionomer
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
glass ionomer-chlorhexidineOther
chlorhexidine will be added to glass ionomer
glass ionomer-titanium dioxide powderOther
titanium dioxide will be added to glass ionomer
glass ionomerOther
glass ionomer will be used without any additives
| Study group | Role | What they receive |
|---|---|---|
| glass ionomer-chlorhexidine | Experimental | Not described Receives: Other: glass ionomer-chlorhexidine |
| glass ionomer -titanium dioxide powder. | Experimental | Not described Receives: Other: glass ionomer-titanium dioxide powder |
| glass ionomer | Active comparator | Not described Receives: Other: glass ionomer |
What is being measured
The primary outcome is the main question the study is designed to answer.
clinical performance
the clinical performance of different restorations will be evaluated by USPHS evaluation criteria
Measured: 9 months
Secondary outcomes (1)
antibacterial effect
bacterial count reduction will be assessed in dentin
Measured: 9 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2022
- Study start1 Sep 2022
- Primary completion1 Sep 2023
- Study completion15 Nov 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dental Caries in ChildrenStudies of the same condition, open and under way.
- More trials run by Ain Shams UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 39 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mariem Wassel, Ain Shams University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05645029
- Sponsor's protocol ID
- FDASU-Rec IR072203
- Status last verified
- Feb 2024
- First submitted
- 1 Dec 2022
- Last updated
- 5 Feb 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Antimicrobial Activity and Clinical Performance of Glass Ionomer Cement Modified With Chlorhexidine and Titanium Dioxide in Primary Molars: A Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT05645029
- Acronym / sponsor ID
- FDASU-Rec IR072203
- Conditions
- Dental Caries in Children
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 39 participants (actual)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 1 Sep 2022 (actual)
- Primary completion
- 1 Sep 2023 (actual)
- Study completion
- 15 Nov 2023 (actual)
- First posted
- 9 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
to investigate the effect of modifying GIC with different formulations on the antibacterial activity and clinical performance in reference to unmodified glass ionomer restorative materials.
Detailed description
The study will be a randomized clinical trial, with a 1:1:1 allocation ratio and parallel arms that will enroll children from the outpatient clinic of pediatric dentistry department, Ain shams University Blinding: Enrolled children, assessors and statistician will be blinded. Randomization: block randomization with blocks of 6. A maximum of 2 primary molars per patient will receive the same treatment.
Allocation concealment: Allocation will be done just before placement of a restoration to avoid performance bias during the cavity preparation. The envelope will be only checked after cavity preparation when the filling material will be chosen
Groups Teeth will be randomly allocated to 3 groups all groups will receive the same cavity preparation and then a different restoration.
- Group A: glass ionomer powder will be mixed with chlorhexidine
- Group B: glass ionomer will be mixed with titanium dioxide powder.
- Group C: will be the positive control, glass ionomer with no additives
Sample Size The sample size: A total number is 39 (13 in each group) is calculated using Epicalc program version 1.02 assuming a power of 80 % and alpha=0.05. The sample size is based on percentage of success of ART restorations at 9 months follow up (GIC with chlorhexidine and GIC with miswak) was 60% and 90%, respectively.13
Intervention:
Teeth will be randomly allocated to the three groups. Care givers and patients involved will be informed about the study procedures, an informed consent form and assent will be obtained. Group A: Conventional glass ionomer cement (Fuji IX, GC, Tokyo, Japan) will be used and modified by incorporating CHX diacetate (0.5% wt) into the powder of the glass ionomer (Fuji IX, GC, Tokyo, Japan) Group B: Conventional glass ionomer cement (Fuji IX, GC, Tokyo, Japan) will be used and modified by incorporating titanium dioxide (3% wt) in glass-based powder component of the GIC.
Group C: Conventional glass ionomer
Cavity preparation and baseline sampling Rubber dam will be placed for isolation of the designated teeth. A step wise caries removal technique will be employed28. Access to the cavity was created using a high-speed dental handpiece fitted with a Meisinger (Hager \& Meisinger - Germany) round diamond bur (801G-16) , and all the caries on the lateral walls, caries in the dentine-enamel junction and undermined enamel was removed.
Using a discoid Lascod (Lascod S.p.A Italy) excavator (#1) elective removal of superficial soft necrotic dentine was attempted, leaving behind demineralized wet, leathery dentine centrally on the pulpal wall (Leathery dentine is characterized by being removed in flakes by the excavator) 8,27 A different sterile excavator of the size will be used with very light pressure to take a sample of dentine from the center of the cavity floor center, the sample will be inserted in a brain heart infusion tube and sent to the microbiology lab within 1 hour then added to the culture to measure the bacterial load for the baseline sample by measuring the colony forming units (CFU) 29,30. Blood agar will be used to quantify the total bacterial count, while mitis-salivaris -bacitracin agar will be used to selectively quantify S.mutans.
After cavity preparation, an endodontic file will be used to record the depth of the cavity to aid with the re-entry, and then the operator will reveal the patient's group by opening an envelope. GC cavity conditioner" (GC Japan) will be applied to the cavity walls for 20 seconds leaving the floor unconditioned then the material will be packed into the cavity using a ball burnisher and pressed into it with a petroleum jelly covered gloves for 30 s (press finger technique). Then the excess material will be removed using a carver, and occlusion will be checked and adjusted, then Equia coat varnish (GC Japan) will be applied.
Follow-up The patients will be recalled at 6 and 9 months for clinical performance evaluation by the USPHS evaluation criteria (table 1). Visual and clinical inspection with 3.5x magnification will be done with the help of a sharp explorer by a blinded secondary investigator.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| glass ionomer-chlorhexidine | Experimental | Other: glass ionomer-chlorhexidine |
| glass ionomer -titanium dioxide powder. | Experimental | Other: glass ionomer-titanium dioxide powder |
| glass ionomer | Active comparator | Other: glass ionomer |
Who may qualify
- Ages
- 4 to 8 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- The teeth will be primary molars selected from patients presented to the outpatient clinic that are
Key exclusion criteria (3 listed)
- .Teeth with pulp involvement, those suffering from pain, irreversible pulpits or pulp necrosis.
- Patients with history of active para-functional oral habits, xerostomia.
- Patients who will have difficulties in cooperating
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| glass ionomer-chlorhexidinechlorhexidine will be added to glass ionomer | Other | glass ionomer-chlorhexidine |
| glass ionomer-titanium dioxide powdertitanium dioxide will be added to glass ionomer | Other | glass ionomer -titanium dioxide powder. |
| glass ionomerglass ionomer will be used without any additives | Other | glass ionomer |
Primary outcome
clinical performance
Time frame: 9 months
the clinical performance of different restorations will be evaluated by USPHS evaluation criteria
1 secondary outcome
antibacterial effect
Time frame: 9 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2024.
- Individual participant dataSharing planned: No
Related trials for Dental Caries in Children
Not yet recruiting
Safety of Intraosseous Anaesthesia in Children With Haemophilia
Haemophilia A, Haemophilia B
Not yet recruiting
This Feasibility Study Will Evaluate the Study Protocols for Treatment and Follow-up Controls of Primary Molars With Caries in Children Treated With Stainless Steel Crowns or Conventional Fillings. Treatment Success and Potential Failures Will be Followed at 3, 6 and 12 Months Post Treatment.
Dental Caries, Early Childhood Caries (ECC)
Recruiting
A Study to Evaluate the Cariostatic Efficacy of Nano Silver Fluoride (NSF) vs. Silver Diamine Fluoride (SDF) in Children
Dental Caries
Not yet recruiting
Effect of Bioactive Glass Varnish on Salivary Parameters in Children: Randomized Controlled Trial
Prevention of Dental Caries
Active, not recruiting
Luting Cements for Prefabricated Zirconia Crown Retention in Primary Anterior Teeth in Children
Dental Caries, Tooth Injuries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing glass ionomer-chlorhexidine, glass ionomer-titanium dioxide powder and glass ionomer in people with Dental Caries in Children, run by Ain Shams University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
clinical performance (time frame: 9 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2024.